Limelight Bio is a privately held, multi-platform, multi-disease biopharmaceutical company developing novel gene therapies and gene editing approaches. The company has developed proprietary technologies, advanced targets, and drug candidates designed to overcome limitations of current AAV-based gene replacement and other gene editing methods. Initial areas of focus include severe retinal, hematologic/metabolic, neurologic, and hearing loss diseases where no current therapies exist. Limelight describes proprietary methods that can persistently correct large genetic defects independent of gene size or mutation pattern without risk of permanent genomic alteration. The company is led by CEO Michael Ehlers and its founders include Jean Bennett and Phil Johnson; it operates in Philadelphia and Cambridge. Limelight Bio raised $75 million in new financing from Apple Tree Partners to accelerate development of multiple drug candidates across its platforms.

Total raised

$75M

Funding rounds

1

Latest round

Equity

Latest activity

Dec 2019